Nevada Clinical Trials

A listing of Nevada clinical trials actively recruiting patient volunteers.

Nevada may be best known for the Las Vegas Strip, but there's plenty to see outside it. Carson City, Reno, and Virginia City all hold their own charms for visitors and residents alike. A vast state with a low population density, it remains the 4th largest producer of gold in the world, even after many Gold Rush "boom towns" have long since been exhausted. As much of the state is dotted with small communities, the best healthcare is centered on larger cities. The Las Vegas area's Sunrise Hospital & Medical Cente is the biggest provider, with more than 640 beds.

Search by Name
Search
Filter by Condition
684 trials found

Discogenic Low Back Pain Registry

NCT04652687

Registry is to observe and trend patterns of care and outcomes for the standard of care treatments of discogenic chronic LBP.

Conditions: Discogenic Pain, Low Back Pain

Transanal Resection of Rectal Lesions With the ColubrisMX ELS System

NCT04651764

This study is a prospective, single-arm, multi-center, open-label, staged clinical study. Overall Objective: To evaluate the safety and effectiveness of the ELS System in subjects undergoing transanal endoluminal procedures in the rectum and distal colon (up to 17 cm from the anal verge). To validate a program for training surgeons and their teams to successfully use the ELS System.

Conditions: Rectal Adenoma, Rectal Polyp, Rectal Lesion
Phase: Not Applicable

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)

NCT04656652

This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.

Conditions: Non-small Cell Lung Cancer

A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

NCT04657016

This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits).

Conditions: Obesity, Overweight

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

NCT04658186

The purpose of the study is to assess the safety and tolerability of UCB0599 and to demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of disease progression over 12 and 18 months in participants diagnosed with early-stage Parkinson's Disease.

Conditions: Early-stage Parkinson's Disease

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

NCT04659174

This is a Phase 3, multicenter, 53-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in subjects with Diagnostic and Statistical Manual-Fifth Edition (DSM-5) schizophrenia who previously completed the treatment period of one of the two Phase 3 double-blind studies, KAR-007 or KAR-009. In this OLE study, all subjects will receive KarXT (a fixed combination of xanomeline 125 mg and trospium chloride 30 mg twice daily [BID]) for ...

Conditions: Schizophrenia

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)

NCT04659161

This is a Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter inpatient study to examine the efficacy and safety of KarXT in adult subjects who are acutely psychotic with a Diagnostic and Statistical Manual Fifth Edition (DSM-5) diagnosis of schizophrenia. The primary objective of the study is to assess the efficacy of KarXT (a fixed combination of xanomeline 125 mg and trospium chloride 30 mg twice daily [BID]) versus placebo in reducing Positive and Negative Synd ...

Conditions: Schizophrenia, Schizophrenia; Psychosis

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

NCT04660344

This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at high risk for recurrence following cystectomy.

Conditions: Muscle-invasive Bladder Cancer

An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.

NCT04660812

This randomized phase 1b/2 open-label study will evaluate the efficacy of etrumadenant (AB928) treatment combinations in patients with metastatic colorectal cancer.

Conditions: Metastatic Colorectal Cancer
Phase: Phase 1/2

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

NCT04662255

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare LOXO-305 to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation could last up to two years, and possibly longer, if the disease does not progress.

Conditions: Lymphoma, Mantle-Cell

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

NCT04663321

The main purpose of this study is to assess the efficacy and safety of daily and intermittent dosing of MK-1942 compared to placebo among participants with Treatment-Resistant Depression (TRD) on a stable course of antidepressant therapy. The dual primary hypotheses of the study are that the daily MK-1942 treatment and/or intermittent MK-1942 treatment are superior to placebo in reducing Montgomery-Asberg Depression Rating Scale (MADRS) score.

Conditions: Treatment Resistant Depression

Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL

NCT04666038

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma